MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Prediction: This Biotech Stock Is Heading for a Once-in-a-Generation Opportunity was originally published by The Motley Fool ...

Sigma Planning Corp trimmed its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 8.7% during the third quarter, according to its most recent disclosure with the ...

"Developer confidence in the market has diminished significantly, resulting in the sale of underperforming new developments," ...